These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 33052490)

  • 1. High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?
    Honore PM; Barreto Gutierrez L; Kugener L; Redant S; Attou R; Gallerani A; De Bels D
    Ann Intensive Care; 2020 Oct; 10(1):139. PubMed ID: 33052490
    [No Abstract]   [Full Text] [Related]  

  • 2. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
    Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H
    Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PK/PD study of tigecycline in severely infected patients with continuous renal replacement therapy.
    Zhao HH; Tang WJ; Yang YX; Cen ZR; Wang LQ
    Int J Clin Pharmacol Ther; 2020 Oct; 58(10):531-538. PubMed ID: 32716292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.
    Gotfried MH; Horn K; Garrity-Ryan L; Villano S; Tzanis E; Chitra S; Manley A; Tanaka SK; Rodvold KA
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
    Conte JE; Golden JA; Kelly MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Jun; 25(6):523-9. PubMed ID: 15885987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.
    Postier RG; Green SL; Klein SR; Ellis-Grosse EJ; Loh E;
    Clin Ther; 2004 May; 26(5):704-14. PubMed ID: 15220014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of tigecycline and comparator agents against common pathogens: Indian experience.
    Veeraraghavan B; Poojary A; Shankar C; Bari AK; Kukreja S; Thukkaram B; Neethimohan RG; Bakhtavachalam YD; Kamat S
    J Infect Dev Ctries; 2019 Mar; 13(3):245-250. PubMed ID: 32040455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z; Chen M; Yu Y; Pan S; Liu Y
    Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
    Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy.
    Beumier M; Roberts JA; Kabtouri H; Hites M; Cotton F; Wolff F; Lipman J; Jacobs F; Vincent JL; Taccone FS
    J Antimicrob Chemother; 2013 Dec; 68(12):2859-65. PubMed ID: 23800905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of 228 non-fermenting gram-negative rods to tigecycline and six other antimicrobial drugs.
    Gómez-Garcés JL; Aracil B; Gil Y; Burillo A
    J Chemother; 2009 Jun; 21(3):267-71. PubMed ID: 19567346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
    Scheetz MH; Qi C; Warren JR; Postelnick MJ; Zembower T; Obias A; Noskin GA
    Antimicrob Agents Chemother; 2007 May; 51(5):1621-6. PubMed ID: 17307973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates.
    Peck KR; Kim MJ; Choi JY; Kim HS; Kang CI; Cho YK; Park DW; Lee HJ; Lee MS; Ko KS
    J Med Microbiol; 2012 Mar; 61(Pt 3):353-360. PubMed ID: 22016557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tigecycline, linezolid and vancomycin on biofilms of viridans streptococci isolates from patients with endocarditis.
    Presterl E; Lassnigg A; Eder M; Reichmann S; Hirschl AM; Graninger W
    Int J Artif Organs; 2007 Sep; 30(9):798-804. PubMed ID: 17918125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
    Park GE; Kang CI; Cha MK; Cho SY; Seok H; Lee JH; Kim JY; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
    Int J Infect Dis; 2017 Sep; 62():26-31. PubMed ID: 28676346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do bacteria isolated from ICU patients 'ESKAPE' antibiotic treatment? In vitro susceptibility of the Enterobacteriaceae family to tigecycline.
    Talaga-Ćwiertnia K; Krzyściak P; Bulanda M
    Anaesthesiol Intensive Ther; 2017; 49(3):210-214. PubMed ID: 28712104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.